Inhibikase Therapeutics, Inc. - IKT

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 14, 2026 SCHEDULE 13G/A Perceptive Advisors LLC 6.9% 10,320,875 View
Aug 14, 2026 SCHEDULE 13G/A Joseph Edelman 6.9% 10,320,875 View
Aug 14, 2026 SCHEDULE 13G/A Perceptive Life Sciences Master Fund, Ltd. 6.9% 10,320,875 View
Aug 14, 2026 SCHEDULE 13G/A Nantahala Capital Management, LLC 4.3% 5,810,487 View
Aug 14, 2026 SCHEDULE 13G/A Wilmot B. Harkey 4.3% 5,810,487 View
Aug 14, 2026 SCHEDULE 13G/A Daniel Mack 4.3% 5,810,487 View
Aug 13, 2026 SCHEDULE 13G/A Sands Capital Life Sciences Pulse Fund II, L.P. 9.3% 13,018,965 View
Aug 13, 2026 SCHEDULE 13G/A Sands Capital Alternatives, LLC 9.3% 13,018,965 View
Aug 13, 2026 SCHEDULE 13G/A SANDS FRANK M. 9.3% 13,018,965 View
Jul 31, 2026 SCHEDULE 13G/A RA Capital Management, L.P. 9.9% 14,653,994 View
Jul 31, 2026 SCHEDULE 13G/A Peter Kolchinsky 9.9% 14,653,994 View
Jul 31, 2026 SCHEDULE 13G/A Rajeev Shah 9.9% 14,653,994 View
Jul 31, 2026 SCHEDULE 13G/A RA Capital Healthcare Fund, L.P. 9.9% 14,653,994 View
Jul 28, 2026 SCHEDULE 13G BlackRock, Inc. 5.9% 7,768,004 View
Jul 17, 2026 SCHEDULE 13G RA Capital Management, L.P. 15.9% 25,000,000 View
Jul 17, 2026 SCHEDULE 13G Peter Kolchinsky 15.9% 25,000,000 View
Jul 17, 2026 SCHEDULE 13G Rajeev Shah 15.9% 25,000,000 View
Jul 17, 2026 SCHEDULE 13G RA Capital Healthcare Fund, L.P. 15.9% 25,000,000 View
May 15, 2026 SCHEDULE 13G/A ADAR1 Capital Management, LLC 9.9% 13,860,028 View
May 15, 2026 SCHEDULE 13G/A ADAR1 Capital Management GP, LLC 8.5% 11,832,998 View
May 15, 2026 SCHEDULE 13G/A Daniel Schneeberger 9.9% 13,860,028 View
May 15, 2026 SCHEDULE 13G/A Commodore Capital LP 9.9% 14,054,940 View
May 15, 2026 SCHEDULE 13G/A Commodore Capital Master LP 9.9% 14,054,940 View
May 15, 2026 SCHEDULE 13G/A Robert Egen Atkinson 9.9% 14,054,940 View
May 15, 2026 SCHEDULE 13G/A Michael Kramarz 9.9% 14,054,940 View
May 15, 2026 SCHEDULE 13G/A Trails Edge Capital Partners, LP 6.1% 8,057,345 View
May 15, 2026 SCHEDULE 13G/A Trails Edge Biotechnology Master Fund, LP 6.1% 8,057,345 View
May 15, 2026 SCHEDULE 13G/A Ortav Yehudai 6.1% 8,057,345 View
May 15, 2026 SCHEDULE 13G/A Perceptive Advisors LLC 8.9% 12,635,875 View
May 15, 2026 SCHEDULE 13G/A Joseph Edelman 8.9% 12,635,875 View
May 15, 2026 SCHEDULE 13G/A Perceptive Life Sciences Master Fund, Ltd. 8.9% 12,635,875 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.